Efficacy and Safety of Vibegron Add-on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor: A Preliminary Study

Ishikawa, Kanji; Tsujimura, Akira; Miyoshi, Miho; Miyoshi, Yuto; Ogasa, Taiki; Hiramatsu, Ippei; Uesaka, Yuka; Nozaki, Taiji; Shirai, Masato; Mitsuhashi, Isao; Sugimura, Sosuke; Mizuno, Taiki; Noto, Kensho; Shigeta, Yasuteru; Honda, Shinichi; Iwata, Shinji; Horie, Shigeo

doi:10.1016/j.urology.2021.01.021

Cited by 5 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vibegron, a new adrenergic β 3 agonist, was confirmed to be effective and safe in several large‐scale clinical trials, 6‐9 and was launched in Japan in November 2018 ahead of other countries. However, there are very few reports that have prospectively evaluated the efficacy and safety of vibegron in real‐world clinical practice 10,11 . Furthermore, only a few studies have evaluated the effectiveness in patients with resistance to previous pharmacotherapy for OAB 12‐14…”

Section: Introductionmentioning

confidence: 99%

Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real‐world clinical practice in Japan, SCCOP study 19‐01

Tachikawa

Kyoda

Fukuta

et al. 2021

LUTS

View full text Add to dashboard Cite

Objective To evaluate the efficacy and safety of vibegron in patients with overactive bladder (OAB) in real‐world clinical practice in Japan. Methods This multicenter, prospective, non‐controlled study consecutively enrolled patients with OAB determined by an OAB symptom score (OABSS) of three points or more and a question 3 (urgency) score of two points or more. A total of 212 patients from 43 institutions were recruited from January 2019 through March 2020. Vibegron, 50 mg, was administrated daily for 8 weeks as first‐line monotherapy (first‐line group, FL), monotherapy switching from antimuscarinics (post‐antimuscarinic group, PA) or mirabegron (post‐mirabegron group, PM) and combination therapy with antimuscarinics (add‐on group). The OABSS was collected at baseline and every 2 weeks. Adverse events were recorded at every visit. Results Of the 212 patients registered, 188 (male 76, female 112) were eligible for analysis (124 in the FL group, 27 in PA, 29 in PM, and eight in the add‐on group). The add‐on group was excluded from further analysis due to its small number. The OABSS (mean ± SD) showed significant improvement in all groups (FL; 8.8 ± 2.5, 3.8 ± 2.8, PM; 9.4 ± 2.2, 4.5 ± 4.0, PM; 8.9 ± 2.5, 4.7 ± 3.3 at 0 and 8 weeks, respectively). The overall incidence of adverse events was 25%. No grade 3 or higher adverse events were observed. Conclusions In the real‐world clinical setting, vibegron is effective and well‐tolerated by OAB patients, including those switching therapy from antimuscarinics and mirabegron.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real‐world clinical practice in Japan, SCCOP study 19‐01

Tachikawa

Kyoda

Fukuta

et al. 2021

LUTS

View full text Add to dashboard Cite

show abstract

“…One small single arm study evaluated the efficacy and safety of vibegron (50mg/day) add-on therapy in 42 men with persistent storage LUTS receiving either an alpha-1 blocker (22 patients) or a PDE5 inhibitor (20 patients) (114). After 12 weeks of treatment a significant improvement of storage symptoms was observed based on the decrease in the total Overactive Bladder Symptom Score.…”

Section: β3-ar Agonists In Combination With Other Drugsmentioning

confidence: 99%

Current pharmacotherapy of overactive bladder

2021

View full text Add to dashboard Cite

Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB.

show abstract

Novel pharmacotherapeutic avenues for bladder storage dysfunction in men

Cho,

Kim

2024

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Efficacy and Safety of Vibegron Add-on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor: A Preliminary Study

Cited by 5 publications

References 26 publications

Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real‐world clinical practice in Japan, SCCOP study 19‐01

Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real‐world clinical practice in Japan, SCCOP study 19‐01

Current pharmacotherapy of overactive bladder

Novel pharmacotherapeutic avenues for bladder storage dysfunction in men

Contact Info

Product

Resources

About